Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024;20(20):1427-1434.
doi: 10.1080/14796694.2024.2354162. Epub 2024 Jun 12.

Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes

Alessandro Rizzo  1 , Lucia Rinaldi  1 , Raffaella Massafra  1 , Antonio Cusmai  1 , Deniz Can Guven  2 , Daniele La Forgia  1 , Agnese Latorre  1 , Francesco Giotta  1
Affiliations
Meta-Analysis

Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes

Alessandro Rizzo et al. Future Oncol. 2024.

Abstract

Aim: There is limited data available regarding the comparison of Sacituzumab govitecan (SG) vs. chemotherapy in metastatic breast cancer patients.Materials & methods: We performed a systematic review and meta-analysis aimed to assess the safety profile of SG vs. chemotherapy for metastatic breast cancer (mBC) clinical trials.Results: The pooled odds ratio for outcomes such as grade 3-4 and all grade neutropenia, leukopenia, anemia and other non-hematological adverse events showed a higher risk for patients receiving SG. No statistically significant differences were reported in terms of grade 3-4 fatigue, all grade nausea, febrile neutropenia and treatment discontinuation due to adverse events.Conclusion: Our data, coupled with a statistically and clinically meaningful survival benefit, support the use of SG for mBC.

Keywords: antibody–drug conjugate; breast; breast cancer; sacituzumab govitecan; triple-negative breast cancer.

Plain language summary

[Box: see text].

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

Figures

Figure 1.
Figure 1.
Diagram of all the trials included and excluded in the present meta-analysis.
Figure 2.
Figure 2.
Risk of bias graph; authors' judgments about each risk of bias item is presented as percentages across all included studies.
Figure 3.
Figure 3.
Forest plot of comparison between sacituzumab govitecan vs. chemotherapy for metastatic breast cancer. The outcome was the odds ratio of grade 3–4 (A) and all grade (B) neutropenia. CI: Confidence interval; OR: Odds ratio.
Figure 4.
Figure 4.
Forest plot of comparison between sacituzumab govitecan vs. chemotherapy for metastatic breast cancer; the outcome was the odds ratio of febrile neutropenia. CI: Confidence interval; OR: Odds ratio.
Figure 5.
Figure 5.
Forest plot of comparison between sacituzumab govitecan vs. chemotherapy for metastatic breast cancer; the outcome was the odds ratio of treatment discontinuation due to adverse events. CI: Confidence interval; OR: Odds ratio.
See this image and copyright information in PMC

References

    1. Grinda T, Rassy E, Pistilli B. Antibody–drug conjugate revolution in breast cancer: the road ahead. Curr Treat Options Oncol. 2023;24(5):442–465. doi: 10.1007/s11864-023-01072-5 - DOI - PMC - PubMed
    1. Fontes MS, Vargas Pivato de Almeida D, Cavalin C, Tagawa ST. Targeted therapy for locally advanced or metastatic urothelial cancer (mUC): therapeutic potential of sacituzumab govitecan. Onco Targets Ther. 2022;15:1531–1542. doi: 10.2147/OTT.S339348 - DOI - PMC - PubMed
    1. Nicolò E, Repetto M, Boscolo Bielo L, Tarantino P, Curigliano G. Antibody–drug conjugates in breast cancer: what is beyond HER2? Cancer J. 2022;28(6):436–445. doi: 10.1097/PPO.0000000000000629 - DOI - PubMed

    2. • A very interesting review discussing the role of antibody–drug conjugates in breast cancer patients.

    1. Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody–drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021;32(6):746–756. doi: 10.1016/j.annonc.2021.03.005 - DOI - PubMed
    1. Rugo HS, Tolaney SM, Loirat D, et al. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2022;8(1):98. doi: 10.1038/s41523-022-00467-1 - DOI - PMC - PubMed

    2. •• The practice-changing phase III ASCENT trial exploring sacituzumab govitecan for triple-negative patients.

MeSH terms